With hundreds of university venture funds, internal commercialisation vehicles and third-party firms the reality in today’s innovation ecosystem, selecting the nominees and the winner for Investment Unit of the Year is increasingly challenging.
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
VW will invest $100m in QuantumScape and form a joint venture with the Stanford spinout to develop batteries for long-range electric vehicles.
Global University Venturing's data review and roundup of funds investing in spinouts and startups
Versant's unusual build-to-buy model has resulted in Roche acquiring a target for MS based on UCSF research and the venture firm launching a new spinout, Pipeline Therapeutics.